UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
Reuters highlights that UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.'s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
據悉，聯合健康集團（NYSE:UNH）週二宣佈，將從2025年1月1日開始從其一些優先報銷清單中移除艾伯維公司（NYSE:ABBV）的暢銷藥物Humira，推薦更低成本的仿製藥版本。
This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.
這一舉措是美國藥品市場上的一種趨勢，由於健康計劃尋求通過推廣替代的高價藥物來降低成本。
Also Read: FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth.
另外閱讀：聯邦貿易委員會的調查發現包括西維斯健康和聯合健康在內的少數幾家藥店福利管理商存在反競爭行爲。
Reuters highlights that Amgen Inc's (NASDAQ:AMGN) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth's lists for commercial health plans.
路透社指出，安進公司（NASDAQ:AMGN）的Amjevita是聯合健康商業健康計劃清單中的一種仿製藥。
With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.
通過這個決定，Optum成爲美國三大最大的藥店福利管理商中唯一不包括Humira的公司。
Cigna Corporation (NYSE:CI) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by CVS Health Inc's (NYSE:CVS) Caremark unit in April.
Cigna公司（NYSE:CI）上個月宣佈，將在2025年從部分清單中移除Humira，並且CVS Health公司（NYSE:CVS）的Caremark部門在4月份做出了類似的決定。
CVS's action led to a swift shift, with more patients transitioning to Sandoz Group AG's (OTC:SDZNY) (OTC:SDZXF) biosimilar version of Humira in just three weeks than in the previous 15 months combined.
CVS的行動導致了一個快速的轉變，僅僅在三個星期內，轉移到Sandoz集團（OTC:SDZNY）（OTC:SDZXF）的Humira的仿製藥版本的患者數量超過了之前15個月的總和。
Cigna plans to cover biosimilars like Boehringer Ingelheim's Cyltezo, Simlandi from Teva Pharmaceutical Industries Ltd (NYSE:TEVA), and Alvotech's (NASDAQ:ALVO) products, including an unbranded version of Sandoz's Hyrimoz, as replacements for Humira.
Cigna計劃覆蓋仿製藥，如拜靈格爾·英格海姆公司的Cyltezo，梯瓦製藥工業有限公司的Simlandi，以及Alvotech公司（NASDAQ:ALVO）的產品，包括Sandoz的Hyrimoz的無品牌版本，作爲Humira的替代品。
UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.
據報道，美國聯合健康公司指出，在FDA將原始藥物與優先的生物相似藥物視爲可以互換之前，患者仍然可以使用Humira。預計FDA將在2025年作出這一判定。
Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like Pfizer Inc (NYSE:PFE) entered the market.
儘管面臨着越來越激烈的競爭，艾伯維公司仍然成功地在2023年保持了美國Humira市場的占主導地位。通過與藥劑福利管理機構有利的洽談，艾伯維甚至在像輝瑞公司等公司進入市場的情況下實現了這一目標。
As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the U.S. over the past year.
根據路透社的報道，儘管在過去一年中美國市場上出現了價格較低的競爭對手，Humira仍然成功地保住了超過80%的患者。
Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to these alternatives.
去年上市後，藥劑福利管理機構在很大程度上影響了患者的使用權，並對醫生轉用這些替代藥物提供了最小的激勵。
In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest operational revenue growth.
據Cantor Fitzgerald在五月份表示，艾伯維公司已經爲吸收Humira的生物相似藥物侵蝕做好了準備，並實現了適度的運營收入增長。
Price Action: UNH stock is down 2% at $587.07 at last check Wednesday.
股票走勢：聯合健康股票最新交易時下跌2%，報587.07美元。
Photo via Shutterstock
圖片來自shutterstock。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech.
- GSk停止單純皰疹病毒疫苗開發，爲現代生物-疫苗、biontech等其他競爭者鋪平道路。
譯文內容由第三人軟體翻譯。
